Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels

In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. At the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by PASI psoriasis, clinical activity score for psoriatic arthritis). The patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. For the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Vulgaris Arthritis Arthritis, Psoriatic Bone Diseases Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Joint Diseases Metabolic Diseases Metabolic Syndrome Musculoskeletal Diseases Nutritional and Metabolic Diseases Psoriasis Psoriatic Arthritis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Istanbul Medeniyet University, Istanbul, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic
Patients older than 18 years
Patients who accept dermatological and rheumatic examination
Patients not receiving systemic treatment related to the disease in the last 1 month

Exclusion criteria

Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis
Patients under 18 years
Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Treatment and study plan

omentin, visfatin

Diagnostic Test

diagnostic blood test

Primary outcomes

omentin

Time frame: 6 months

Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels
visfatin

Time frame: 6 months

Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue.

Sponsors and collaborators

Lead sponsor

Istanbul Medeniyet University

Other

Registry information

Official study title

The Prevalence of Metabolic Syndrome in Patients With Psoriasis and Psoriatic Arthritis and Its Correlation With Disease Severity and Serum Omentin-1 and Visfatin Levels

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2019
First posted: Apr 30, 2019
Registry last updated: Jun 17, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed